REYON Pharmaceutical Co., Ltd. (KRX: 102460)
South Korea
· Delayed Price · Currency is KRW
12,820
-490 (-3.68%)
Dec 19, 2024, 9:00 AM KST
REYON Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Operating Revenue | 149,842 | 151,071 | 154,039 | 142,801 | 130,034 | 131,558 | Upgrade
|
Other Revenue | -0 | -0 | - | - | -0 | - | Upgrade
|
Revenue | 149,842 | 151,071 | 154,039 | 142,801 | 130,034 | 131,558 | Upgrade
|
Revenue Growth (YoY) | -0.49% | -1.93% | 7.87% | 9.82% | -1.16% | 6.97% | Upgrade
|
Cost of Revenue | 76,707 | 73,347 | 73,475 | 64,348 | 58,282 | 58,058 | Upgrade
|
Gross Profit | 73,135 | 77,724 | 80,564 | 78,453 | 71,752 | 73,500 | Upgrade
|
Selling, General & Admin | 63,041 | 64,306 | 66,286 | 63,151 | 61,008 | 60,361 | Upgrade
|
Research & Development | 3,143 | 8,375 | 6,705 | 9,725 | 6,584 | 3,724 | Upgrade
|
Other Operating Expenses | 1,061 | 981.05 | 942.46 | 958.94 | 884.68 | 788.67 | Upgrade
|
Operating Expenses | 69,086 | 75,951 | 76,116 | 76,909 | 70,098 | 66,878 | Upgrade
|
Operating Income | 4,048 | 1,773 | 4,448 | 1,545 | 1,654 | 6,622 | Upgrade
|
Interest Expense | -184.54 | -195.53 | -122.2 | -111.19 | -178.01 | -116.33 | Upgrade
|
Interest & Investment Income | 410.98 | 802.87 | 994.76 | 527.96 | 992.16 | 1,744 | Upgrade
|
Earnings From Equity Investments | -1,478 | -960.18 | -1,968 | 1,684 | -475.29 | -358.51 | Upgrade
|
Currency Exchange Gain (Loss) | 129.12 | 124.67 | -91.55 | 12.43 | 4.21 | 14.27 | Upgrade
|
Other Non Operating Income (Expenses) | 1,176 | 4,938 | -945.79 | 514.97 | 430.31 | -273.94 | Upgrade
|
EBT Excluding Unusual Items | 4,102 | 6,483 | 2,315 | 4,173 | 2,427 | 7,632 | Upgrade
|
Gain (Loss) on Sale of Investments | -3,184 | -3,183 | 4,262 | 1,125 | 1,573 | 97.92 | Upgrade
|
Gain (Loss) on Sale of Assets | 691.56 | 732.32 | 317.22 | 547.04 | 367.42 | -5.16 | Upgrade
|
Other Unusual Items | -273.27 | - | - | - | - | -1,167 | Upgrade
|
Pretax Income | 1,336 | 4,032 | 6,894 | 5,845 | 4,368 | 6,557 | Upgrade
|
Income Tax Expense | 720.28 | 448.59 | -539.77 | 307.51 | 523.26 | 1,613 | Upgrade
|
Earnings From Continuing Operations | 615.8 | 3,583 | 7,434 | 5,537 | 3,844 | 4,944 | Upgrade
|
Minority Interest in Earnings | - | - | - | - | - | 1.87 | Upgrade
|
Net Income | 615.8 | 3,583 | 7,434 | 5,537 | 3,844 | 4,946 | Upgrade
|
Preferred Dividends & Other Adjustments | - | - | 75 | 125 | - | - | Upgrade
|
Net Income to Common | 615.8 | 3,583 | 7,359 | 5,412 | 3,844 | 4,946 | Upgrade
|
Net Income Growth | -92.70% | -51.80% | 34.25% | 44.03% | -22.28% | 268.33% | Upgrade
|
Shares Outstanding (Basic) | 18 | 18 | 18 | 18 | 17 | 17 | Upgrade
|
Shares Outstanding (Diluted) | 18 | 18 | 18 | 18 | 17 | 17 | Upgrade
|
Shares Change (YoY) | -1.91% | 0.46% | 3.03% | 4.05% | 1.01% | -0.80% | Upgrade
|
EPS (Basic) | 33.57 | 195.38 | 414.51 | 305.44 | 225.75 | 293.40 | Upgrade
|
EPS (Diluted) | 33.20 | 195.00 | 407.18 | 305.00 | 225.75 | 293.40 | Upgrade
|
EPS Growth | -92.72% | -52.11% | 33.50% | 35.10% | -23.06% | 271.31% | Upgrade
|
Free Cash Flow | -19,613 | -20,225 | -54,404 | -105,293 | -47,708 | -63,113 | Upgrade
|
Free Cash Flow Per Share | -1069.34 | -1102.71 | -2979.96 | -5942.30 | -2801.53 | -3743.71 | Upgrade
|
Dividend Per Share | 150.000 | 150.000 | 150.000 | 250.000 | 200.000 | 343.137 | Upgrade
|
Dividend Growth | 0% | 0% | -40.00% | 25.00% | -41.71% | -30.00% | Upgrade
|
Gross Margin | 48.81% | 51.45% | 52.30% | 54.94% | 55.18% | 55.87% | Upgrade
|
Operating Margin | 2.70% | 1.17% | 2.89% | 1.08% | 1.27% | 5.03% | Upgrade
|
Profit Margin | 0.41% | 2.37% | 4.78% | 3.79% | 2.96% | 3.76% | Upgrade
|
Free Cash Flow Margin | -13.09% | -13.39% | -35.32% | -73.73% | -36.69% | -47.97% | Upgrade
|
EBITDA | 8,169 | 6,555 | 8,981 | 6,210 | 6,219 | 10,710 | Upgrade
|
EBITDA Margin | 5.45% | 4.34% | 5.83% | 4.35% | 4.78% | 8.14% | Upgrade
|
D&A For EBITDA | 4,120 | 4,782 | 4,534 | 4,666 | 4,565 | 4,088 | Upgrade
|
EBIT | 4,048 | 1,773 | 4,448 | 1,545 | 1,654 | 6,622 | Upgrade
|
EBIT Margin | 2.70% | 1.17% | 2.89% | 1.08% | 1.27% | 5.03% | Upgrade
|
Effective Tax Rate | 53.91% | 11.13% | - | 5.26% | 11.98% | 24.60% | Upgrade
|
Advertising Expenses | - | 76.91 | 106.09 | 56.01 | 152.9 | 265.77 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.